12:00 AM
 | 
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adecatumumab: Phase Ib data

Additional data from an open-label, dose-escalation Phase Ib trial in 22 patients with relapsed metastatic breast cancer showed that adecatumumab plus docetaxel resulted in an overall response rate (ORR) of 24% and a clinical benefit rate, which includes partial/complete responses or stable disease...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >